A Clinical Trial of JAK Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction
Stanford University
Summary
We intend, with this study, to prove that blocking the molecular mechanisms whose blockade prevents VIDD in animals, will indeed prevent the development of VIDD in humans as well. We believe that this evidence will serve as the required basis for proceeding with large, ICU-based clinical trial(s) of a drug to prevent VIDD.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Patients undergoing esophagectomy Exclusion Criteria: * Patients with more than mild pulmonary dysfunction * Patients with any neuromuscular disease that might compromise diaphragm function * Patients with abnormal liver or kidney function * Patients taking any immunosuppressant medication (including prednisone) or antifungal medications * History of tuberculosis * Weight loss of \>5% of body weight over previous 6 months * Pregnancy
Interventions
- DrugTofacitinib 10 MG [Xeljanz]
administered twice daily for two days
- DrugPlacebo to match Tofacitinib
administered twice daily for two days
Location
- Stanford University Medical CenterStanford, California